Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

Kyongbo Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,909	4,128	4,477	6,348	4,290	11,439
Short-Term Investments	2,000	2,000	870	870	-	9,543
Cash & Short-Term Investments	3,909	6,128	5,347	7,218	4,290	20,983
Cash Growth	-24.96%	14.60%	-25.92%	68.25%	-79.55%	209.99%
Accounts Receivable	53,197	51,624	56,160	50,202	46,906	50,501
Other Receivables	417.11	686.7	697.94	597.63	988.69	2,226
Receivables	53,614	52,311	56,858	50,799	47,895	52,727
Inventory	90,380	90,585	70,664	57,443	57,670	62,173
Prepaid Expenses	933.09	1,311	1,610	115.43	913.7	1,439
Other Current Assets	1,684	1,606	1,423	749.74	397.53	870.73
Total Current Assets	150,521	151,941	135,902	116,326	111,166	138,192
Property, Plant & Equipment	103,317	99,852	96,073	93,919	95,677	90,100
Long-Term Investments	10,712	11,121	13,676	11,935	14,384	11,828
Other Intangible Assets	4,402	4,008	3,641	3,221	3,355	3,091
Long-Term Deferred Tax Assets	14,051	13,565	13,203	11,951	10,179	7,609
Other Long-Term Assets	4,704	3,399	3,810	3,194	2,218	2,420
Total Assets	287,708	283,887	266,305	240,545	236,979	253,239
Accounts Payable	14,951	14,951	22,775	14,742	16,404	14,293
Accrued Expenses	2,284	3,537	3,398	2,793	2,553	2,538
Short-Term Debt	96,430	89,271	73,095	63,900	55,234	61,218
Current Portion of Long-Term Debt	22.5	45	90	90	90	90
Current Portion of Leases	1,070	1,074	1,078	280.59	787.02	765.11
Current Income Taxes Payable	202.68	86.85	118.34	166.28	-	976.16
Other Current Liabilities	23,965	23,695	17,707	13,596	13,746	13,883
Total Current Liabilities	138,926	132,660	118,261	95,569	88,814	93,764
Long-Term Debt	-	-	45	135	225	315
Long-Term Leases	893.55	1,043	1,629	106.58	250.75	876.89
Other Long-Term Liabilities	2,589	2,548	1,988	1,030	1,061	634.15
Total Liabilities	143,623	137,733	121,924	96,841	91,278	97,182
Common Stock	11,953	11,953	11,953	11,953	11,953	11,953
Additional Paid-In Capital	40,067	40,067	40,067	40,067	40,067	40,067
Retained Earnings	96,570	98,333	96,033	94,695	94,587	104,207
Comprehensive Income & Other	-4,505	-4,199	-3,672	-3,012	-907.41	-171.32
Shareholders' Equity	144,085	146,154	144,381	143,704	145,701	156,057
Total Liabilities & Equity	287,708	283,887	266,305	240,545	236,979	253,239
Total Debt	98,416	91,433	75,936	64,512	56,587	63,265
Net Cash (Debt)	-94,506	-85,305	-70,589	-57,294	-52,296	-42,283
Net Cash Per Share	-3951.09	-3568.22	-2942.80	-2439.66	-2190.88	-1766.95
Filing Date Shares Outstanding	23.96	23.91	23.91	23.91	23.91	23.91
Total Common Shares Outstanding	23.96	23.91	23.91	23.91	23.91	23.91
Working Capital	11,596	19,281	17,641	20,757	22,352	44,429
Book Value Per Share	6014.07	6113.48	6039.33	6011.00	6094.52	6527.70
Tangible Book Value	139,684	142,146	140,741	140,483	142,346	152,966
Tangible Book Value Per Share	5830.35	5945.84	5887.05	5876.26	5954.19	6398.43
Land	-	30,146	28,633	27,569	23,874	19,510
Buildings	-	82,779	81,336	79,341	76,851	73,165
Machinery	-	125,238	119,358	113,325	111,022	97,341
Construction In Progress	-	7,959	1,856	1,444	1,729	6,698

Source: S&P Global Market Intelligence. Standard template. Financial Sources.